acellular pertussis vaccine (including diptheria and tetanus toxoids)
Trade name: Tripedia
Vaccineapproved
Approved
Jan 29, 1997
Adacel Technologies Limited is an air traffic management company that develops and implements air traffic management systems, air traffic control simulation and training. — Wikipedia
Clinical trial activity
192 trials · 101 clinical orgs · 2 marketing orgs
Phase 1
22
Phase 2
117
Phase 3
87
Phase 4
48
Earliest trial started Sep 1, 1992 (NCT00004800)
Timeline
1990s
- Jan 1, 1992
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1997
Earliest Phase 2 Sponsor(trial)
- Jan 29, 1997
GlaxoSmithKline — Earliest FDA Approval
- Jan 29, 1997
GlaxoSmithKline — NDA Secondary Org
- Jan 29, 1997
GlaxoSmithKline — NDA Organization
- Dec 9, 1999
Sanofi-Aventis — NDA Secondary Org
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Alzheimer Disease · Phase 1/Phase 2
- Apnea · Phase 4
- Arthritis, Rheumatoid · Phase 4
- Chickenpox · Phase 3
- Communicable Diseases · Phase 2
- Dengue · Phase 3
- Dengue Virus · Phase 2
- Dermatitis, Atopic · Phase 2
- Diarrhea · Phase 1/Phase 2
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 4
- Diphtheria-Tetanus-Pertussis Vaccine · Phase 4
- Diphtheria Toxoid · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Dysentery, Bacillary · Phase 1/Phase 2
- Esophageal and Gastric Varices · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Fever · Phase 4
- Haemophilus Infections · Phase 4
- Haemophilus influenzae · Phase 4
- Haemophilus influenzae type b · Phase 4
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 4
- Hepatitis B · Phase 4
- HIV Infections · Phase 1
- Hospitalization · Phase 4
- Immune System Diseases · Phase 4
- Infant, Premature · Phase 4
- Infant, Premature, Diseases · Phase 4
- Influenza, Human · Phase 4
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Measles · Phase 3
- Measles-Mumps-Rubella Vaccine · Phase 4
- Meninges · Phase 2
- Meningitis · Phase 4
- Meningitis, Bacterial · Phase 3
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 4
- Meningococcal Vaccines · Phase 2
- Mortality · Phase 4
- Multiple Sclerosis · Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Mumps · Phase 3
- Mumps Vaccine · Phase 2
- Neisseria meningitidis · Phase 3
- Neoplasms, Glandular and Epithelial · Phase 3
- Ovarian Neoplasms · Phase 2
- Papillomavirus Infections · Phase 4
- Pertussis Vaccine · Phase 4
- Pneumococcal Infections · Phase 3
- Pneumonia, Pneumococcal · Phase 4
- Poliomyelitis · Phase 4
- Poliovirus Vaccines · Phase 2
- Pre-Eclampsia · Phase 4
- Pregnancy · Phase 4
- Pregnancy Complications · Early Phase 1
- Pregnant People · Phase 2/Phase 3
- Respiratory Syncytial Virus Infections · Phase 4
- Respiratory Tract Infections · Phase 2
- Rotavirus Infections · Phase 4
- Rubella · Phase 3
- Rubella Vaccine · Phase 2
- Seizures, Febrile · Phase 4
- Severe Dengue · Phase 3
- Streptococcal Infections · Phase 2/Phase 3
- Tetanus · Phase 4
- Trismus · Phase 1
- Typhoid Fever · Phase 2
- Uterine Cervical Neoplasms · Phase 4
- Vaccination · Phase 4
- Vaccines · Phase 4
- Whooping Cough · Phase 4
- Yellow Fever · Phase 3
Mechanism of action
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
- Corynebacterium diphtheriaeImmunity, active
Corynebacterium diphtheriae immunity, active
- Clostridium tetaniImmunity, active
Clostridium tetani immunity, active
Approval history
- approvedJan 29, 1997
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAdacel ↗
- WikipediaDPT vaccine ↗
Also known as
- acel-immune
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- adacel
- adacel
- covaxis
- covaxis
- diphtheria & tetanus toxoids & acellular pertussis vaccine adsorbed
- diphtheria & tetanus toxoids & acellular pertussis vaccine adsorbed
- dtap
- td1ap
- td5ap
- tdap
- triaxis
- tripedia
- tripedia
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07203755 | Phase 1 | Oct 22, 2025 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT07097012 | Phase 4 | Oct 16, 2025 | Canadian Center for Vaccinology, Canadian Immunization Research Network, Dalhousie University, Government of Canada, University of British Columbia, University of Ottawa |
| NCT07112144 | Phase 3 | Jun 13, 2025 | Changchun BCHT Biotechnology Co., Government of China |
| NCT06891872 | Phase 4 | May 31, 2025 | Sinovac Biotech Co., Ltd |
| NCT06920069 | Phase 4 | May 15, 2025 | Chinese Academy of Medical Sciences |
| NCT06803524 | Phase 4 | May 13, 2025 | BioNet-Asia Co., Ltd., Mahidol University |
| NCT06857370 | Phase 3 | Mar 23, 2025 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06708286 | Phase 2/Phase 3 (Phase 3) | Dec 18, 2024 | Tianjin Cansino Biotechnology Inc |
| NCT06494475 | Phase 2/Phase 3 (Phase 3) | Dec 17, 2024 | Minervax ApS |
| NCT06639074 | Phase 2 | Nov 12, 2024 | Mayo Clinic |
| NCT06184542 | Phase 1 | Dec 23, 2023 | Chinese Academy of Medical Sciences, Government of China |
| NCT06344065 | Phase 3 | Dec 21, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT06056050 | Phase 1 | Dec 6, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06015308 | Phase 2 | Oct 6, 2023 | Sanofi |
| NCT05951725 | Phase 3 | Aug 11, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT05870618 | Phase 4 | May 31, 2023 | China National Biotec Group Co., Ltd, Government of China |
| NCT05870631 | Phase 4 | May 31, 2023 | China National Biotec Group Co., Ltd, Government of China |
| NCT05183516 | Phase 1/Phase 2 (Phase 2) | May 1, 2023 | Mindful Diagnostics and Therapeutics, Mindful Diagnostics and Therapeutics, LLC |
| NCT05827874 | Phase 1 | Apr 12, 2023 | — |
| NCT05662852 | Phase 2 | Mar 31, 2023 | ABO Holdings, Inc. |
Showing 20 of 192 trials
Page 1 / 10
Organizations
Research & Development (101)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 48 | 48 | 5 | 1999 |
| GlaxoSmithKline | For profit | 37 | 36 | 3 | 1997 |
| Sanofi-Aventis | For profit | 20 | 6 | 5 | 1999 |
| Government of China | Government | 13 | 3 | 3 | 2013 |
| Novartis | For profit | 11 | 11 | 3 | 2006 |
| Pfizer | For profit | 10 | 10 | 4 | 1997 |
| China National Biotec Group Co., Ltd | For profit | 7 | 5 | 2 | 2019 |
| Tianjin Cansino Biotechnology Inc | For profit | 6 | 6 | 2 | 2019 |
| Beijing Tiantan Bio Co., Ltd | For profit | 5 | 0 | 2 | 2019 |
| Merck | For profit | 5 | 5 | 2 | 2000 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 4 | 1992 |
| Dalhousie University | Academic/Hospital | 4 | 3 | 2 | 2007 |
| Centers for Disease Control and Prevention (CDC) | Government | 3 | 0 | 1 | 2016 |
| Duke University | Academic/Hospital | 3 | 3 | 1 | 2016 |
| Mahidol University | Academic/Hospital | 3 | 2 | 3 | 2018 |
| Statens Serum Institut | Academic/Hospital | 3 | 2 | 2 | 2003 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 2 | 2 | 1 | 2021 |
| BioNet-Asia Co., Ltd. | For profit | 2 | 1 | 2 | 2020 |
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 1 | 2015 |
| Chengdu Institute of Biological Products Co.,Ltd. | Government | 2 | 0 | 1 | 2019 |
101 organizations
Page 1 / 6
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA2 | Jan 29, 1997 |
| GlaxoSmithKline | For profit | NDA | Jan 29, 1997 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1999 |